Changjiang Pharmaceutical Group Co.,Ltd. Posted 137.6 Million Yuan Net Loss in First Three Quarters of 2023

Changjiang Pharmaceutical Group Co.,Ltd. (长江医药控股股份有限公司) (300391.SZ) reported a net loss of 137.6 million yuan in the first three quarters of 2023, reversing a net profit of 103.1 million yuan for the same period in the previous year.

Meanwhile, the company posted 1 billion yuan in revenue, down 28.2% year-on-year.

At the end of the reporting period, it had 3.7 billion yuan in total assets and 2.2 billion yuan in total liabilities, with a liability-to-asset ratio of 57.6%.